Search

en analyse af børsretlige problemstillinger

Background: This study was carried out in Guinea-Bissau ’ s capital Bissau among inpatients and outpatients attending for tuberculosis (TB) treatment within the study area of the Bandim Health Project, a Health and Demographic Surveillance Site. Our aim was to assess the variability between 2 physicians in performing the Bandim tuberculosis score (TBscore), a clinical severity score for pulmonary TB (PTB), and to compare it to the Karnofsky performance score (KPS). Method : From December 2008 to July 2009 we assessed the TBscore and the KPS of 100 PTB patients at inclusion in the TB cohort and/or at 1 or more follow-up visits; 61 baseline and 130 follow-up double assessments were obtained. Results : The inter-observer variability of the TBscore (5 symptoms and 6 clinical fi ndings) varied from slight to almost perfect agreement. For the TBscore, all 3 severity classes (SC I – III) were observed, while the KPS only yielded 2 of its 3 possible classes. The grading of PTB patients into severity classes showed moderate agreement for both the TBscore ( κ w 0.52, 95% confi dence interval0.46 – 0.56) and the KPS ( κ w 0.49, 95% confi dence interval 0.33 – 0.65). The intra-class correlation coeffi cient (ICC) was larger for the TBscore than for the KPS (0.822 vs 0.632). Conclusions : The Bandim TBscore had an acceptable inter-observer variability, seemed to be more disease-related, and performed better than the KPS. Background: This study was carried out in Guinea-Bissau's capital Bissau among inpatients and outpatients attending for tuberculosis (TB) treatment within the study area of the Bandim Health Project, a Health and Demographic Surveillance Site. Our aim was to assess the variability between 2 physicians in performing the Bandim tuberculosis score (TBscore), a clinical severity score for pulmonary TB (PTB), and to compare it to the Karnofsky performance score (KPS). Method: From December 2008 to July 2009 we assessed the TBscore and the KPS of 100 PTB patients at inclusion in the TB cohort and/or at 1 or more follow-up visits; 61 baseline and 130 follow-up double assessments were obtained. Results: The inter-observer variability of the TBscore (5 symptoms and 6 clinical findings) varied from slight to almost perfect agreement. For the TBscore, all 3 severity classes (SC I-III) were observed, while the KPS only yielded 2 of its 3 possible classes. The grading of PTB patients into severity classes showed moderate agreement for both the TBscore (κ(w) = 0.52, 95% confidence interval 0.46-0.56) and the KPS (κ(w) = 0.49, 95% confidence interval 0.33-0.65). The intra-class correlation coefficient (ICC) was larger for the TBscore than for the KPS (0.822 vs 0.632). Conclusions: The Bandim TBscore had an acceptable inter-observer variability, seemed to be more disease-related, and performed better than the KPS.

fremstillingen indeholder en analyse af de børsretlige regler

Submitted by Anabela Morais (ajmorais@porto.ucp.pt) on 2011-12-06T17:13:59Z No. of bitstreams: 1 2008_DIREITO_Antunes_JoseEngracia-dig2.PDF: 534051 bytes, checksum: 831ffc4875c2eebd13c5d1d3609ae781 (MD5) Made available in DSpace on 2011-12-14T12:23:00Z (GMT). No. of bitstreams: 1 2008_DIREITO_Antunes_JoseEngracia-dig2.PDF: 534051 bytes, checksum: 831ffc4875c2eebd13c5d1d3609ae781 (MD5) Previous issue date: 2008

På initiativ af forfatterne til det følgende blev der i 2007 dannet en europæisk gruppe af fremtrædende selskabsretseksperter med henblik på at udforme en »European Model Company Law Act« (EMCLA). Gruppen holdt sit første møde i Århus i september 2007.

On 27 and 28 September 2007, a commission formed on the initiative of the authors held its first meeting in Aarhus, Denmark to deliberate on its goal of drafting a "European Model Company Law Act" (EMCLA). This project, outlined in the following pages, aims neither to force a mandatory harmonization of national company law nor to create a further, European corporate form. The goal is rather to draft model rules for a corporation that national legislatures would be free to adopt in whole or in part. Thus, the project is thought as an alternative and supplement to the existing EU instruments for the convergence of company law. The present EU instruments, their prerequisites and limits will be discussed in more detail in Part II, below. Part III will examine the US experience with such "model acts" in the area of company law. Part IV will then conclude by discussing several topics concerning the content of an EMCLA, introducing the members of the EMCLA Working Group, and explaining the Group's preliminary working plan.